Skip to content
En
Sv
Governance
Back
Governance
Governance Structure
General Meeting
General Meetings
Nomination Committee
Nomination Committees
Board of Directors
Work of the Board of Directors
Board Committees
Executive Management Team
Remuneration
Internal Control
Audit
Articles of Association
Corporate Governance Reports
Career
Media
Back
Media
Press releases
Image bank
Subscribe
Contact us
BioArctic websites
Sweden
Norway
Finland
Denmark transparancy reporting
En
Sv
Menu
About us
Back
About us
Our Purpose
History
Culture and values
Leadership
Testimonials
Research and Strategy
Back
Research and Strategy
Our Technology
Alzheimer’s disease
Parkinson’s disease
ALS – Amyotrophic lateral sclerosis
Other indications
BrainTransporter™ Technology
Pipeline
Sustainability
Back
Sustainability
Our Approach to Sustainability
Sustainable Innovation
Transfers of value to healthcare
Sustainable Business
Code of Conduct
Policies
Whistleblower
Investors
Back
Investors
Annual report 2024
The share
Financial reports and presentations
Conference presentations
Capital Markets Day 2025
Shareholder information
Share capital development
Dividend
Ownership structure
Analysts and estimates
Privacy policy Shareholders
Press releases
Prospectus
Calendar
IR contacts
Subscribe
Partnering
Back
Partnering
Why partner with BioArctic
Our partnerships
Collaboration principles
Search for:
Search
Loading...
The share
Governance
Back
Governance
Governance Structure
General Meeting
General Meetings
Nomination Committee
Nomination Committees
Board of Directors
Work of the Board of Directors
Board Committees
Executive Management Team
Remuneration
Internal Control
Audit
Articles of Association
Corporate Governance Reports
Career
Media
Back
Media
Press releases
Image bank
Subscribe
Contact us
BioArctic websites
Sweden
Norway
Finland
Denmark transparancy reporting
Search
Search for:
Press
to
Search
Loading...
The share
BioArctic
Investors
Conference presentations
Lecanemab demonstrates highly selective binding to ...
Loading...
The share
Lecanemab demonstrates highly selective binding to a-beta protofibrils isolated from Alzheimer’s disease brains – Poster at ADPD 2025
April 7, 2025
Documents
PA_Poster for ADPD 2025_Lecanemab demonstrates highly...MJohannesson mfl.